The EMA has approved daraxonrasib, an innovative drug that doubles survival in patients with metastatic pancreatic cancer, but its commercialization in Europe could face obstacles related to costs and production capacity. #Oncologia #TumorePancreas #FarmaciInnovativi (translated)









